These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28789636)

  • 21. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
    Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
    Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.
    Otake H; Matsumoto S; Mashima H
    Medicine (Baltimore); 2017 Apr; 96(16):e6635. PubMed ID: 28422861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.
    Bastida G; Marín-Jiménez I; Forés A; García-Planella E; Argüelles-Arias F; Tagarro I; Fernandez-Nistal A; Montoto C; Aparicio J; Aguas M; Santos-Fernández J; Boscá-Watts MM; Ferreiro-Iglesias R; Merino O; Aldeguer X; Cortés X; Sicilia B; Mesonero F; Barreiro-de Acosta M
    Dig Liver Dis; 2022 Jan; 54(1):76-83. PubMed ID: 34244110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
    Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
    Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.
    Mandel MD; Balint A; Golovics PA; Vegh Z; Mohas A; Szilagyi B; Szabo A; Kurti Z; Kiss LS; Lovasz BD; Gecse KB; Farkas K; Molnar T; Lakatos PL
    Dig Liver Dis; 2014 Nov; 46(11):985-90. PubMed ID: 25156871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
    Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
    Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months.
    Little RD; Chu IE; Ward MG; Sparrow MP
    Dig Dis Sci; 2022 Jan; 67(1):259-262. PubMed ID: 33763785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
    Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
    Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
    George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
    Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.